Daiwa Securities Group Inc. Raises Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Daiwa Securities Group Inc. lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 37,651 shares of the medical research company’s stock after acquiring an additional 1,828 shares during the quarter. Daiwa Securities Group Inc.’s holdings in IQVIA were worth $8,922,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Canada Pension Plan Investment Board increased its position in IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after purchasing an additional 211,653 shares during the period. Farallon Capital Management LLC boosted its stake in shares of IQVIA by 3.1% during the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after purchasing an additional 86,870 shares in the last quarter. Impax Asset Management Group plc increased its holdings in IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after buying an additional 157,809 shares during the period. Legal & General Group Plc boosted its position in IQVIA by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock valued at $320,170,000 after acquiring an additional 11,715 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of IQVIA by 5.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,197,084 shares of the medical research company’s stock valued at $253,125,000 after acquiring an additional 60,827 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on IQV shares. Deutsche Bank Aktiengesellschaft dropped their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Barclays reduced their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. BTIG Research lowered their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Argus raised IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. lowered their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Price Performance

Shares of NYSE:IQV opened at $204.02 on Tuesday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company’s 50 day moving average is $221.96 and its 200 day moving average is $226.98. The company has a market cap of $37.03 billion, a PE ratio of 26.77, a price-to-earnings-growth ratio of 2.08 and a beta of 1.51.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.